Ventripoint Issues Shares for Debt Settlement and Awards Option Grants

Executive Summary

• Ventripoint Diagnostics received TSX Venture Exchange approval to settle $427,696.35 of debt by issuing 4,276,964 common shares at $0.10 per share.
• The company granted 2,516,500 stock options (exercise price $0.12) to directors, officers, employees, contractors and consultants, with vesting periods ranging from immediate to three years.
• Since the prior update, option exercises generated $81,800 in gross proceeds; there remain 16,683,500 outstanding options, of which 14,555,167 have vested, and 2.0 million options are available for future grants.

Key Details

• Debt Settlement: 4,276,964 common shares issued to settle $427,696.35 debt owed to arm’s‑length creditors; share price $0.10 per share.
• Hold Period: Shares subject to a four‑month‑and‑one‑day hold period.
• Option Grants (Jan 20 2026): 2,516,500 options granted at an exercise price of $0.12; terms range from 2 to 10 years, vesting over up to three years.
• Allocation: 200,000 options awarded to directors; 1,300,000 options awarded to officers (some also directors).
• Recent Exercise Activity: Since June 17 2025, 780,000 options exercised at a weighted‑average price of ~$0.105 per share, yielding $81,800 gross proceeds.
• Outstanding Options: 16,683,500 options outstanding with exercise prices between $0.10 and $0.50 (weighted‑average $0.17); 14,555,167 of these have vested.
• Future Grant Capacity: Approximately 2.0 million options remain available for future grants under the approved Stock Option Plan.

Notable Quotes

(No direct quotes were provided in the release.)